Vivanza Biosciences Ltd

Vivanza Biosciences Ltd announced that its statutory auditor, M/s Shivam Soni & Co, Chartered Accountants, has issued an audit report with an unmodified opinion on the company's audited financial results for the quarter and year ended March 31st, 2026. This declaration complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has formally recorded this report.

Vivanza Biosciences Ltd held a Board of Directors meeting on July 9, 2026. The board approved the transfer of 300 equity shares from the Unclaimed Suspense Account to Ms. Manju Narendra Kothari after KYC verification. Additionally, Mr. Vishal Sureshbhai Katarmal was appointed as the Company Secretary and Compliance Officer, effective the same date. The board also took note of the DPT-3 Return of Deposit for the financial year ended March 31, 2026, and an agreement for a Plastic Film Manufacturing Project in the Kyrgyz Republic.

Vivanza Biosciences Limited has entered into a Strategic Cooperation, Investment & Technology Transfer Agreement with Mr. Kalybek Uulu Bekturgan, who will act as a facilitator for investment promotion, government liaison, and industrial project development in the Kyrgyz Republic. The agreement focuses on establishing a Plastic Film Manufacturing Project, involving technology transfer, project design, machinery sourcing, government liaison, investment facilitation, skill development, import-export promotion, and financing assistance. There is a possibility of forming a Joint Venture Company, subject to definitive agreements and approvals. Currently, no monetary consideration has been paid or received, and the arrangement is non-binding. This strategic move aims to expand Vivanza's international presence and explore new growth opportunities.

Vivanza Biosciences Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 1st, 2026, and will remain in effect until 48 hours after the declaration of its standalone and consolidated financial results for the quarter ended June 30th, 2026. The measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and applies to promoters, directors, KMPs, designated persons, connected persons, and their immediate relatives. The company will announce the board meeting date for financial results in due course.

Vivanza Biosciences Ltd held a Board of Directors meeting on June 18, 2026. The board approved the appointment of M/s. Dharti Shah & Co. as the Internal Auditor for the Financial Year 2026-2027. Additionally, Mr. Hemant Amrish Parikh was appointed as an Additional Non-Executive Non-Independent Director, effective from the same date. The meeting also transacted other routine business.

Vivanza Biosciences Ltd's Board of Directors convened on June 18, 2026, approving key appointments and transactions. M/s. Dharti Shah & Co. were appointed as the Internal Auditor for FY 2026-2027. Mr. Hemant Amrish Parikh was appointed as an Additional Non-Executive Non-Independent Director. The board also authorized Mr. Sarang Bharatbhai Pathak to sign the financial statements for FY ended March 31, 2026, and approved the transfer of unverified shares to the Unclaimed Suspense Account.

Vivanza Biosciences Ltd has announced a Board of Directors meeting scheduled for June 18, 2026. The agenda includes authorizing Mr. Sarang Bharatbhai Pathak to sign financial statements for FY26, appointing M/s. Dharti Shah & Co. as Internal Auditors for FY27, and considering the appointment of Mr. Hemant Amrish Parikh as a Non-Executive Non-Independent Director. The board will also discuss the transfer of unverified shares to the Unclaimed Suspense Account and authorize the RTA for processing such shares upon verification. Meeting details will be available on the company's website.

Vivanza Biosciences Ltd. announces that Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, concerning the disclosure of related party transactions, will not be applicable for the quarter and year ending March 31, 2026. As of March 31, 2025, the company's paid-up equity share capital is ₹4,00,00,000 and its net worth is ₹4,02,03,752.40, which falls below the threshold of ₹10 Crores and ₹25 Crores respectively, as per Regulation 15(2) of SEBI (LODR) Regulations, 2015.

Vivanza Biosciences Ltd. announced audited standalone financial results for the quarter and year ended March 31, 2026. The board approved the results and noted the resignations of Hemant A. Parikh as a Non-Executive Director (effective March 17, 2026) and Chaitra Arora as Company Secretary & Compliance Officer (effective April 30, 2026). The board also approved the reconstitution of various committees, including the Audit Committee and Nomination & Remuneration Committee, effective May 7, 2026.

Vivanza Biosciences Ltd's Board of Directors approved the audited standalone and consolidated financial results as per Indian Accounting Standards (Ind AS) for the quarter and year ended March 31, 2026. The board also took note of the resignations of Mr. Hemant Amrish Parikh as a Non-Executive Director (effective March 17, 2026) and CS Chaitra Arora as Company Secretary & Compliance Officer (effective April 30, 2026). Additionally, the Board approved the reconstitution of various committees, including the Audit Committee.